Brief: Processa Pharmaceuticals Announces PCS12852 Successfully Improves The Clinical Symptoms Associated With Gastroparesis In Phase 2A Trial

Processa Pharmaceuticals

14/12/2022 13:35

Dec 14 (Reuters) - Processa Pharmaceuticals Inc
 PCSA.O :
    * PROCESSA PHARMACEUTICALS ANNOUNCES PCS12852 SUCCESSFULLY
IMPROVES THE CLINICAL SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN
PHASE 2A TRIAL
    * PROCESSA PHARMACEUTICALS INC - PCS12852 WAS SHOWN TO BE
GENERALLY WELL-TOLERATED
    * PROCESSA PHARMACEUTICALS INC - THERE WERE NO CLINICALLY
SIGNIFICANT CARDIOVASCULAR, UNEXPECTED, SEVERE, OR SERIOUS
ADVERSE EVENTS REPORTED DURING STUDY
    * PROCESSA PHARMACEUTICALS INC - PROCESSA WILL BE DESIGNING
PHASE
2B TRIAL AND SUBMITTING IT TO THEIR IND
    * PROCESSA PHARMACEUTICALS INC - EPENDING ON PRIORITIES,
FUNDING,
AND LICENSING/PARTNERING OPPORTUNITIES A PHASE 2B TRIAL COULD BE
INITIATED IN 2023
    * PROCESSA PHARMA-0.5 MG DAILY DOSE OF PCS12852 GIVEN OVER
28 DAYS
IN GASTROPARESIS PATIENTS SUCCESSFULLY IMPROVED SYMPTOMS IN
CLINICALLY MEANINGFUL WAY

Source text for Eikon:  ID:nGNX2tDzkL 
Further company coverage:  PCSA.O 
 ((Reuters.Briefs@thomsonreuters.com;))